Tafamidis

• Target :

  Others

• Related Pathways :

  Others

• Purity :

  0.9965

• Bioactivity :

  Tafamidis (Fx-1006A) is a kinetic stabilizer of transthyretin (TTR) that prevents amyloidogenesis by wild-type and mutant TTRs. It binds to TTR with negative cooperativity (Kd1: 3 nM; Kd2: 278 nM) to stabilize the TTR dimer-dimer interface and inhibit tetrameric dissociation. Tafamidis stabilizes wild-type and clinically significant V30M and V122I mutant TTR amyloidogenic homotetramers (EC50s: 2.7-3.2 ?M) under fibril-promoting, denaturing, and physiological conditions in vitro. It stabilizes TTR heterotetramers containing wild-type and mutant subunits ex vivo in human plasma derived from patients carrying V30M or V1221 mutations when used at a concentration of 7.2 ?M. Formulations containing tafamidis have been used for the treatment of familial amyloid polyneuropathy.

• Smiles :

  ClC=1C=C(C=2OC=3C(N2)=CC=C(C(O)=O)C3)C=C(Cl)C1

• Molecular Formula :

  C14H7Cl2NO3

• Molecular Weight :

  308.12

• Shipping Conditions :

  Cool pack

• Storage Temperature :

  -20°C

• CAS Number :

  594839-88-0